Accent Therapeutics launched a Phase I/II clinical trial last year to begin testing a small molecule inhibitor of KIF18A in ovarian cancers.

Products released at this year's meeting covered a broad range of applications from sustainable labware to protein assays to instruments.

This eBook explores how innovation and shifting patient expectations are reshaping modern diagnostics—and advancing progress toward global STI elimination goals.

Michelle Lee, PhD, unpacks how physical AI that integrate scientific reasoning with the wet lab will accelerate biological discovery.

Ion mobility adds a powerful new dimension to biopharma separations as complex therapeutics outgrow traditional LC–MS.

AI can help protein engineers optimize the transcription enzymes used to make mRNA-based vaccines and therapeutics, say the authors of a new study.

Designing a high-density fed-batch, E. coli-based strategy to produce recombinant GLP-1 cuts upstream production costs 20–30%.

Unchained Labs launched Stuntman during the SLAS meeting in Boston: an automation platform that combines native, natural-language AI with flexible hardware.

Biologists have engineered adeno-associated viruses that are better at capsid filling, potentially resulting in higher productivity.

Eli Lilly will shell out $2.4 billion to acquire genetic medicine developer Orna Therapeutics and has committed up to $8.85 billion to launch a seventh collaboration with Innovent Biologics. Both ...

The company, based in Norcross, GA, manufactures more than 900 DNA and RNA isolation products used in clinical research, biotechnology, genomics, and agriculture.

A new study has found bacterial sugars that cause neurodegenerative immune response, providing a mechanism for therapeutic intervention.